Development, Reliability, and Validity of a New Preference and Satisfaction Questionnaire  by Gold, Deborah T. et al.
w
s
t
U
1
P
d
V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 9 – 1 1 1 6
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva lDevelopment, Reliability, and Validity of a New Preference and
Satisfaction Questionnaire
Deborah T. Gold, PhD1,*, Rob Horne, PhD, MRPharmS2, Cheryl D Coon, PhD3, Mark A Price, MA, MEd3, Jeff Borenstein, MD4,†,
Sepideh F. Varon, PhD5, Sacha Satram-Hoang, PhD4, David Macarios, MBA4
1Duke University Medical Center, Durham, NC, USA; 2The School of Pharmacy, University of London, London, UK; 3RTI Health Solutions, Research Triangle
Park, NC, USA; 4Amgen Inc., Thousand Oaks, CA, USA; 5ALLERGAN, Irvine, CA, USAA B S T R A C Ti
t
(
0
i
j
0
b
t
r
e
n
K
t
CObjectives: Existing questionnaires that assess preference and/or sat-
isfaction with postmenopausal bone loss treatments were reviewed
and determined to be inadequate for the assessment of an oral pill
versus a subcutaneous injection. The Preference and Satisfaction
Questionnaire (PSQ) was developed to assess preference, satisfaction,
and bother with a weekly oral tablet versus a once every 6 months
subcutaneous injection for treatment of postmenopausal bone loss.
Methods: Questions were developed based on literature review and
expert input. Content validity of the PSQ in this patient population was
assessed among current or previous bisphosphonate users in group
interviews, and item comprehension and readability were also evalu-
ated. Reliability, validity, and structure of the questionnaire were as-
sessed in two phase 3 randomized clinical trials. Results: Twenty-four
omen participated in cognitive interviews and found the PSQ under-
tandable and acceptable. Subsequently, 1583 trial participants took
he PSQ. Interitem correlations, ranging from 0.50 to 0.97 for preference O
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oi:10.1016/j.jval.2011.06.010tems, 0.85 to 0.94 for pill-satisfaction items, and 0.84 to 0.92 for injec-
ion-satisfaction items, and a well-fitting confirmatory factor analysis
root mean square error of approximation 0.04, nonnormed fit index
.99, and rootmean square residual 0.08) supported the structure of the
nstrument. Cronbach’s alpha reliability values for pill satisfaction, in-
ection satisfaction, pill bother, and injection bother were 0.93, 0.89,
.82, and 0.61, respectively. Discriminative validity was indicated with
etter satisfaction and bother scores being related to adherence and
he absence of adverse events. Conclusions: The PSQ is a valid and
eliable measure and may be a valuable tool to assess patient prefer-
nce and satisfaction with a weekly oral tablet and 6-month subcuta-
eous injection for postmenopausal bone loss.
eywords: preference, questionnaire development, reliability, satisfac-
ion, validation.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Osteoporosis is a major public health concern, affecting an esti-
mated 200 million people worldwide [1]. In the United States
and Europe approximately one-third of postmenopausal
women have osteoporosis [2]. Osteoporosis is characterized by
increased bone resorption and decreased bone mass, resulting
in microarchitectural deterioration of the skeleton and in-
creased fracture risk. Osteoporosis is initially an asymptomatic
disease, with few clinical symptoms before fracture. Studies
have shown that compliance and persistence with pharmaceu-
tical treatments for osteoporosis are suboptimal, with many
patients discontinuing therapy within the first year [3–5], and
likely not receiving the full therapeutic benefit [5,6]. Reasons for
nonadherence are multifactorial and include convenience and
frequency of the dosing regimen, perceived efficacy, and side
effects [7,8]. Results from a large, longitudinal study of post-
menopausal women who were prescribed treatments for osteo-
porosis found that women who were less satisfied with their
osteoporosis treatment were more likely to discontinue treat-
† Current affiliation: Cedars-Sinai Health System, Los Angeles,
* Address correspondence to: Deborah T. Gold, Duke University Ce
niversity Medical Center, Durham, NC 27710, USA.
E-mail: dtg@geri.duke.edu.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.ment within the first year than women who were more satisfied
with their osteoporosis treatment [9].
Bisphosphonates are the therapeutic agents most frequently
used to treat postmenopausal bone loss. These agents are avail-
able as oral tablets to be taken daily, weekly, or monthly, and
intravenous infusions given quarterly or annually. Denosumab
(Prolia®) is a fully human monoclonal antibody to RANK ligand, a
ey mediator of osteoclast formation, function, and survival. De-
osumab is administered as a twice-yearly subcutaneous injec-
ion. Two randomized phase 3 trials directly compared the efficacy
f denosumab with branded alendronate (Fosamax) in postmeno-
ausal women with low bone mass [10,11]. In both studies, deno-
umab treatment significantly increased bone mineral density at
he total hip compared with alendronate treatment. In a separate
linded, randomized, placebo-controlled, phase 3 trial, deno-
umab was shown to significantly reduce the incidence of new
ertebral, nonvertebral, and hip fractures in postmenopausal
omenwith osteoporosis [12]. The less frequent administration of
enosumab could promote greater adherence with treatment, re-
ulting in better therapeutic outcomes for patients.
SA.
for the Study of Aging and Human Development, Box 3003, Duke
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1110 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 9 – 1 1 1 6Patient preference and satisfaction are important determi-
nants of adherence to therapies for chronic conditions, including
osteoporosis [4,13–15]. Preference is a relative measure of desir-
bility, and has a strong theoretical basis in economics and psy-
hology. It can be measured as a choice between alternatives or
caled (degree of desirability) [16]. Treatment satisfaction mea-
sures the degree to which patient expectations with different at-
tributes of their treatment are met [17,18]. Attributes of treatment
may include perceived efficacy, presence and/or severity of side
effects, convenience, and the bother with treatment. Further un-
derstanding of the factors that influence patient perception of os-
teoporosis treatments may result in improved educational efforts
to increase adherence.
To date, no existing questionnaire adequately captures patient
preference for and satisfaction with a subcutaneous injection ver-
sus oral pill for the treatment of postmenopausal bone loss. Thus,
we developed the Preference and Satisfaction Questionnaire (PSQ)
to compare patient preference for and satisfaction with two
agents for the treatment of postmenopausal osteoporosis: a sub-
cutaneous injection given every 6 months and an oral pill taken
weekly. The objective of this article is to describe the development
of and establish evidence for the reliability and validity of the PSQ
in evaluating patient preference for and satisfaction with treat-
ment for low bone mass and osteoporosis.
Methods
PSQ development
A literature review using Medline was conducted to assess the
existing evidence on patient preference for and satisfaction with
medical therapies. The review focused on English language arti-
cles published from 1990 to 2006 that reported results from pref-
erence and satisfaction studies in patients with osteoporosis,
preference and satisfaction studies in other disease settings—es-
pecially in primary care—and patient preference and satisfaction
related to injections. A total of 348 articles were identified; 49 were
retrieved. Subsequent to a more detailed evaluation, 32 publica-
tions were selected for data abstraction and detailed review. An
additional five studies were identified from the reference lists, for
a total of 37 studies. These publications covered a broad range of
medical conditions, including osteoporosis, pain, migraine, diabe-
tes, chronic obstructive pulmonary disease, and asthma. Injection
was discussed in 13 studies (intramuscular, subcutaneous, or in-
travenous). The majority of studies (n  28) assessed preference
once, generally at the end of study, whereas the balance (n  9)
assessed preference atmore than one time point during the study.
Preferencewas assessed using a single item in 18 studies andmul-
tiple items in 11 studies; eight studies did not indicate the number
of items used to assess preference. In 34 studies preference was
measured along with other items such as utility, satisfaction, or
symptoms. Many studies (n  23) did not provide details on the
alidity of the instruments and only seven studies provided a pub-
ished source for the instrument (we did not retrieve the source to
etermine validity).
Existing questionnaires that assess preference and/or satisfac-
ion with treatment also were reviewed to create an initial pool of
opics. We identified nine studies in osteoporosis that evaluated
references [19–27]. These studies evaluated daily versus daily
22,24], weekly versus daily [21,23,25,26], or weekly versus
onthly oral treatment regimens [20,27]; none evaluated injec-
ions. Only four studies were identified that compared treatment
ith oral tablets to an injection. In two of the studies the oral and
ubcutaneous injection were given with the same dosing fre-
uency for treatment of migraines [28,29]. A third study evaluated
ral versus intravenous versus intramuscular dosing regimens fortreatment of acute pain [30]. The fourth study evaluated monthly
intramuscular injection versus oral dosing for contraception [31].
Three experts in addition to the study’s authors reviewed the
nitial item pool generated from the literature to identify relevant
oncepts, ensure item clarity, and eliminate redundancy to gener-
te an initial set of items. The draft PSQ contained 34 questions
elating to preference, satisfaction, bother, convenience, long-
erm use, and lifestyle fit. For nine items (1–3, 6, and 9–13) patients
ere asked to choose in terms of preference, bother, or satisfac-
ion, one of the following: the pill, the injection, or neither (indi-
ating any difference in preference or satisfaction between the
wo treatments). For 20 items (4a–4f, 5a–5f, 7a–7d, and 8a–8d) pa-
ients used a five-point response scale to specify the degree of
other (scored from not bothered at all to severely bothered) or
atisfaction (scored from not satisfied at all to very satisfied) di-
ected at each of the treatments. For five items (14a–14e) patients
elected the degree to which she agreed or disagreed with the
uestion or statement on a five-point response scale (strongly
gree to strongly disagree). In these items, patients compared
reatment regimens with one treatment being favored over the
ther.
PSQ evaluation
In-depth interviews were conducted by experienced facilitators
with two different focus groups in two cities in the United States
(n 12/group). Participants (n 24) were postmenopausal women
who currently used or had used a bisphosphonate within the past
three years. The semistructured interviews included open-ended
questions addressing the effects of the disease and disease treat-
ment on social, psychological, physical functioning, and perceived
well-being. Patients completed the draft questionnaire and were
debriefed on the PSQ item relevance, interpretation of content,
clarity of wording, format and length, and concepts. Revisions
weremade to questionwording and the layout of the survey based
on feedback from the first focus group. The revised version of the
PSQ was administered to the second focus group and additional
revisionsweremade based on feedback. Subjects’ commentswere
recorded during the survey and the cognitive debrief in addition to
the detailed notes generated by the interviewer. To evaluate if the
order of response options influenced the choicesmade by the sub-
ject, participants in the first focus group were given a version of
the questionnaire where injection preceded oral for all response
options whereas participants in the second focus group were
given a version of the questionnaire where oral preceded injection
for all response options.
The pilot English questionnaire was then culturally adapted
into 17 languages for use in 14 countries in accordance with the
Translation and Cultural Adaptation group for linguistic valida-
tion of quality of life questionnaires [32]. The linguistic validation
process involves forward and backward or harmonized translations
of theoriginalAmericanEnglishquestionnaire, followedbycognitive
debriefing of patients from each country to ensure items are under-
stood across cultures consistently. The culturally adapted question-
naires were included in two randomized, double-blind, double-
dummy phase 3 trials for psychometric validation.
The PSQ was administered to participants enrolled in the
phase 3 DECIDE and STAND trials. Details on the design of the
DECIDE and STAND studies are published elsewhere [10,11]. In
brief, both studies compared the efficacy and safety of twice-
yearly subcutaneous injection of denosumab (60 mg) with weekly
oral alendronate (70 mg) in postmenopausal women with low
bone mass. Subjects received both an oral tablet weekly and a
subcutaneous injection once every 6 months. In the DECIDE study
(N  1189), patients had no or very limited prior exposure to oral
bisphosphonates, whereas in the STAND study (N  504) patients
had received bisphosphonate therapy for a minimum of 6months
before study enrollment. In both studies, patients took the PSQ at
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1111V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 9 – 1 1 1 6the month 12 or early termination visit before any study-visit pro-
cedures. The protocols for the DECIDE and STAND studies were
approved by the ethics committee or independent review board at
each site and were conducted in accordance with standards pro-
vided in the Declaration of Helsinki. Patients in both trials pro-
vided written informed consent before initiation of any study-
related procedures.
Because the order inwhich patients are asked about each treat-
ment (pill or injection) could influence their responses, two ver-
sions of the PSQ were developed to eliminate the effect of order
bias: Version A references the weekly pill first, and Version B ref-
erences the 6-month injection first. Subjects randomly received
either Version A or Version B. This enabled assessment of if re-
sponse choice order introduced systemic bias.
Item scoring
To compare responses across items and PSQ versions, PSQ items
were rescored, as necessary, to ensure scoring was directionally
the same. Preference items, where the pill and the injection were
compared head-to-head within an item, were rescored so that
positive values indicated a preference for the injection and nega-
tive values indicated a preference for the pill. Items 1 through 3, 6,
and 9 through 13 were scored so that pill preference equaled 1,
injection preference equaled 1, and no preference equaled 0.
Components in item 14 were scored so that strong agreement for
injection preference equaled 2 and strong disagreement for in-
jection preference equaled 2. Pill and injection bother, which
weremeasured independently using items 4 and 5, were scored so
that no bother equaled 0 and severe bother equaled 4. Pill and
injection satisfaction, which were measured independently using
items 7 and 8, were scored so that not satisfied equaled 0 and very
satisfied equaled 4.
Statistical analyses
Data were not imputed for the PSQ. All statistical tests were two-
tailed and performed with a type 1 error rate of 1% (alpha  0.01),
nless otherwise stated.
Descriptive statistics. Item-level response frequencies and per-
entageswere considered for each of the PSQ items overall, and by
anguage, treatment (active pill or active injection), and PSQ ver-
ion (A or B). Item-level descriptive statistics were computed for
ach subgroup (overall for each protocol and by language, treat-
ent, and version). These statistics describe the relations among
tems and the appropriateness of pooling the data across transla-
ion, study, and version.
Instrument structure. A preliminary evaluation of the instru-
ent structure was conducted using inter-item correlations.
any items within the PSQ have similar content, and correlations
etween these items (within-subscale) were expected to be sub-
tantial. Correlations between the remaining items on the scale
between-subscale) should be significant but lower than the with-
n-subscale item pairs.
Exploratory factor analysis (EFA) was conducted with data
rommonth 12 in each study using a 50% randomsample stratified
y protocol, country, and treatment. EFA was performed using a
atrix of polychoric correlations with unweighted least squares
stimation and quartimin rotation. The size of the eigenvalues [33]
nd scree test results [34] from a principal components analysis
elped inform the decision regarding the number of factors un-
erlying the PSQ items. The final decision as to the number of
actors in the PSQ was based on the size and pattern of the factor
oadings.
The model proposed based on EFA results was evaluated using
onfirmatory factor analysis on the remaining 50% random sample
n LISREL version 8.80 [35] with polychoric correlations, weighted
east squares estimation, and a full asymptotic covariance matrix. triteria for model fit included the chi-square test, the root mean
quare residual [36], the comparativefit index [37], thenonnormedfit
ndex [38], and the root mean square error of approximation. Modi-
cation indices generated in LISREL were considered to inform revi-
ions to the proposed structure of the new PSQ.
Reliability. The internal consistency for each of the proposed
cales of the PSQwas evaluated by computingCronbach’s coefficient
lpha [39]. The approximate range of optimal alphas suggested by
treiner andNorman [40] is between 0.70 and 0.90, indicating a set of
tems that are strongly related and capable of supporting a unidi-
ensional scoring structure, but not redundant.
Discriminative validity.Analysis of covariance (ANCOVA)models
ere used to examine mean differences on the PSQ at the last
tudy time point, using protocol, language, treatment, and version
s covariates. Evidence in support of discriminative validity was
valuated utilizing comparisons between patients who adhered to
reatment and those who did not and between patients who ex-
erienced an adverse event judged by the investigators as possibly
elated to the investigational drug versus those who did not. Sig-
ificant differences for each of these comparisons would indicate
scale that can discriminate between known groups.
Results
Demographics
Focus group participants. The mean age of the women who volun-
teered to participate in the focus groups was 62.3  7.0 years. All
had been diagnosed with postmenopausal osteoporosis and had
received either branded alendronate (n  15) or branded risedro-
nate (n  9). At the time of the focus group 16 participants were
currently taking oral bisphosphonates, whereas eight had discon-
tinued bisphosphonates. Of those who stopped bisphosphonate
therapy, three women had done so in the past 3 months, whereas
five women had done so within the past 3 years.
Many volunteers in the focus groups indicated the survey was
generally straightforward, with some items requiring clarification
(e.g., mode of administration). They did not suggest that any items
be deleted. Two participants thought that some questions were
repetitive. In terms of new issues identified, six participants re-
ferred to cost. Based on the feedback from the focus group partic-
ipants, the changes were generally limited to clarifying some of
the questions.
DECIDE and STAND participants Overall, 1583 patients enrolled
in the DECIDE and STAND studies were administered the PSQ.
Sixty-nine percent of the sample came from the DECIDE study,
and the active treatment and PSQ version were split nearly evenly
across the whole sample. Women in these studies were predomi-
nantly from the United States and took the US English version of
the PSQ. Eighteen languages in 14 countrieswere represented. The
women were primarily white (87%) and their mean age was 65.4
years (Table 1).
Descriptive statistics
Item-response frequencies and descriptive statistics were consid-
ered for each of the PSQ items overall and by protocol, language,
active treatment, and PSQ version andwere previously reported [41].
Items did not appear to differ across protocol and active treat-
ent; response frequencies for each category were within 10% of
ach other across groups, and item means were within one stan-
ard deviation of each other across groups. The same pattern of
onsistent response frequencies held across the two PSQ versions
or all items except items 14a through 14e. These items asked for
greement with statements that referred to the weekly pill being
ore convenient, preferable, tolerable, or likely to continue overhe 6-month injection in Version A (vice versa for Version B). For
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1112 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 9 – 1 1 1 6example, Version A might ask if “the weekly pill is more conve-
nient than the 6-month injection” whereas Version B would ask if
“the 6-month injection is more convenient than the weekly pill.”
In both versions of the PSQ patients responded in the direction of
preferring the injection over the pill, but the Version A responses
were predominantly in the “disagree” category, whereas the Ver-
sion B responses were predominantly in the “strongly disagree”
category (after reverse-scoring). This inconsistency suggests that
responses to items 14a through 14e are not consistent across the
two versions, with responses to Version B showing stronger pref-
erence for the injection than responses to Version A. Thus, items
14a through 14e are not equivalent across versions and cannot be
used interchangeably.
Instrument structure
The interitem correlations of all 34 items were examined as a pre-
liminary evaluation of the instrument structure. A number of
items on the PSQ have similar content, and correlations between
these itemswere expected to be substantial (r 0.40). The range of
ithin-domain interitem correlations is presented in Figure 1 (ab-
olute values). Although some of these interitem correlations do
ot reach 0.40, nearly all are substantial in magnitude. The pro-
Table 1 – Patient demographics.
Group n (%)
Language
US English 520 (32.8)
Danish 177 (11.2)
Canadian English 172 (10.9)
Polish 118 (7.5)
Canadian French 105 (6.6)
Portuguese 105 (6.6)
US Spanish 66 (4.2)
Argentina Spanish 63 (4.0)
Estonian 47 (3.0)
Australian English 37 (2.3)
Belgian French 33 (2.1)
German 32 (2.0)
Spanish 27 (1.7)
French 24 (1.5)
Italian 22 (1.4)
Belgian Dutch 17 (1.1)
UK English 13 (0.8)
Russian 5 (0.3)
Randomized controlled trial
DECIDE 1100 (69.5)
STAND 483 (30.5)
Active treatment
Pill 785 (49.6)
Injection 798 (50.4)
PSQ version
A 788 (49.8)
B 795 (50.2)
Race
White 1381 (87.2)
Hispanic or Latino 145 (9.2)
Asian or Japanese 24 (1.5)
Black 17 (1.1)
Other 11 (0.7)
American Indian or Alaskan Native 3 (0.2)
Native Hawaiian or Pacific Islander 2 (0.1)
Age in years, mean (SD) 65.4 (8.3)
PSQ, Preference and Satisfaction Questionnaire.osed structure of the instrument is supported by the relativelyarge correlations among preference items (range 0.50–0.97), pill
atisfaction items (range 0.85–0.94), and injection satisfaction
tems (range 0.84–0.92). Although ranges for pill bother and injec-
ion bother items were wide (range 0.26–0.81 and 0.18–0.85, re-
pectively), most correlations are greater than or equal to 0.40 (11
ut of 15 [74%] pill bother items; 10 out of 15 [67%] injection bother
tems). The proposed structure of the instrument is further sup-
orted through interitem correlations for items not on the same
omain being much smaller in magnitude than the within-sub-
cale correlations (range 0.00–0.83). The proportion of correlations
chieving coefficients of greater than or equal to 0.40 among items
ithin the same domain (124 out of 133 [93.2%]) is larger than the
roportion of coefficients greater than or equal to 0.40 among
tems across domains (141 out of 428 [32.9%]).
An EFA was conducted on the full set of 34 items using data
rom a 50% random subsample stratified by protocol, language,
ctive treatment, and PSQ version (n 676). The eigenvalues from
PCA indicated one strong factor underlying the 34 PSQ items
eigenvalue of 12.48; one factor explaining 37% of the variance),
ith a possible second factor (eigenvalue of 5.00; second factor
xplaining an additional 15% of the variance). Five additional
igenvalues exceeded Kaiser’s (33) rule of thumb of 1.0 (2.14, 2.05,
.50, 1.29, and 1.13), though these factors would explain negligible
ariance (6%, 6%, 4%, 4%, and 3%). Still, because there are as many
s five concepts that can be identified in the PSQ items (preference,
ill satisfaction, injection satisfaction, pill bother, and injection
other), models with one to five factors were considered in EFA.
The models that retained one, two, three, or four factors did not
xhibit parsimony. Although simpler models are usually preferred,
he one-factor model had a number of small factor loadings
e.g., 0.40), and the two-, three-, and four-factormodels had anum-
er of substantial cross-factor loadings. The five-factormodel (Table
) had a substantial factor loading for almost every item ( 0.40), and
o item loaded highly on more than one factor. In addition, the
roupings of the items into factors fit with the content of the items;
he five factors appear to be: 1) preference; 2) pill satisfaction; 3) in-
ection satisfaction; 4) pill bother; and 5) injection bother.
Although the EFA supported a clear five-factor model with the
actors matching with the concepts previously identified, there
ppears to be substantial redundancy in the items. Multiple items
esigned to measure similar concepts were developed for the PSQ
o that the final set of items could be selected after psychometric
valuation, and item reduction was necessary before proceeding
ith CFA to minimize excessive item relation that could make
stimation difficult. Preference is measured by a number of items,
ut only two items were retained, item 1 (“which do you prefer?”),
hichmeasures preference in themost straight-forwardmanner,
nd item 13 (‘which would you take long-term?”), which asks spe-
ifically about the choice for long-term treatment and may relate
o adherence. Pill satisfaction and injection satisfaction were also
easured by several items, but items 7 and 8 were retained be-
Fig. 1 – Range of within-domain interitem correlations for
all items on the Preference and Satisfaction Questionnaire.
1113V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 9 – 1 1 1 6cause theymeasure satisfactionwith the pill and satisfactionwith
the injection separately. Items 7d (“weekly pill—overall satisfac-
tion”) and 8d (“every 6-months injection—overall satisfaction”)
were removed because they were redundant with the three pill
satisfaction items (i.e., 7a, 7b, and 7c) and the three injection sat-
isfaction items (i.e., 8a, 8b, and 8c), respectively. Finally, because
the two treatment modalities have a different set of potentially
bothersome side effects or circumstances, the pill bother items
(item 4) and injection bother items (item 5) were retained.
Results of a five-factor CFA conducted on the resulting 20-item
PSQ (available in Supplementary Materials available at doi:10.1016/
j.jval.2011.06.010) usingdata fromthe remaining50%subsample (n
721), are presented in Table 3. The CFA model showed excellent
model fit with substantial loadings for most factors. Items 4b
(“weekly pill—stomach upset”) and 5b (“every 6-months injection—
stomach upset”) had smaller factor loadings as compared with the
other items on their factors, but this is not surprising for symptom
items. These factors are expected to measure pill bother and injec-
tion bother, respectively, and a patient could report being bothered
by the treatment without reporting stomach upset as measured by
these items. Stomach bother resonated with patients in cognitive
testing, so these items were retained despite their deflated factor
loadings to ensure that these side effects are represented in the final
questionnaire and because Cronbach’s alpha values for the scales
Table 2 – PSQ exploratory factor analysis rotated factor loa
Item Factor 1
(preference)
s
1 – Prefer 0.84
2 – Continue 0.89
3 – Lifestyle 0.87
4a – Pill bother 0.07
4b – Pill stomach upset bother 0.01
4c – Pill fasting bother 0.04
4d – Pill taking with water bother 0.00
4e – Pill being upright bother 0.01
4f – Pill routine bother 0.03
5a – Injection bother 0.06
5b – Injection stomach upset bother 0.00
5c – Injection pain at site bother 0.05
5d – Injection pain after bother 0.04
5e – Injection routine bother 0.03
5f – Injection needle bother 0.03
6 – Bothersome 0.40
7a – Pill frequency satisfaction 0.07
7b – Pill mode satisfaction 0.01
7c – Pill convenience satisfaction 0.05
7d – Pill overall satisfaction 0.01
8a – Injection frequency satisfaction 0.01
8b – Injection mode satisfaction 0.00
8c – Injection convenience satisfaction 0.04
8d – Injection overall satisfaction 0.06
9 – Frequency satisfaction 0.86
10 – Mode satisfaction 0.87
11 – Convenient 0.95
12 – Overall satisfaction 0.93
13 – Long-term 0.99
14a – Convenient 0.75
14b – Preferable 0.82
14c – Tolerate 0.58
14d – Continue 0.85
14e – Take long time 0.77
Note: n  676 for this analysis; correlations  0.40 in bold.including the items were consistent with an acceptable degree ofinternal validity. There were no modification indices for correlated
error terms on the same factor that were large enough to evoke con-
cern about item redundancy within subscale.
Reliability
The reduced PSQ consists of 20 items measuring five domains.
Subscale scores were calculated by taking an average of the items
on that domain. An examination of Cronbach’s alpha if-item-de-
leted suggested that one item response could be missing from the
pill satisfaction, injection satisfaction, and pill bother subscales
and still achieve adequate scale reliability, whereas no item re-
sponses could be missing from the injection bother subscale. The
Cronbach’s alpha reliability values for the subscales are 0.93 for
pill satisfaction, 0.89 for injection satisfaction, 0.82 for pill bother,
and 0.61 for injection bother. Cronbach’s alpha is unavailable for
the two preference items because they do not comprise a subscale.
Discriminative validity
The ability of the PSQ to distinguish between known groups was
measured through a series of ANCOVAs predicting adherence to
treatment (only measured for patients receiving the active pill)
and experience of adverse events (AEs) related to the investiga-
tional drug (Table 4). Treatment adherence was measured by pill
s.
or 2
ill
ction)
Factor 3
(injection
satisfaction)
Factor 4
(pill bother)
Factor 5
(injection
bother)
.04 0.04 0.06 0.02
.00 0.01 0.07 0.02
.05 0.01 0.04 0.02
.26 0.04 0.58 0.02
.03 0.06 0.42 0.01
.11 0.07 0.72 0.01
.05 0.07 0.57 0.02
.12 0.08 0.69 0.00
.20 0.08 0.70 0.01
.02 0.17 0.05 0.45
.10 0.05 0.37 0.03
.05 0.10 0.09 0.88
.06 0.11 0.02 0.70
.08 0.14 0.19 0.38
.03 0.14 0.07 0.28
.24 0.11 0.14 0.07
.81 0.09 0.08 0.04
.87 0.04 0.02 0.01
.91 0.05 0.03 0.01
.92 0.07 0.04 0.01
.06 0.81 0.00 0.02
.06 0.88 0.04 0.02
.03 0.90 0.02 0.03
.06 0.87 0.00 0.03
.07 0.02 0.02 0.05
.05 0.02 0.03 0.02
.05 0.03 0.02 0.04
.02 0.00 0.05 0.03
.06 0.06 0.07 0.03
.03 0.00 0.10 0.03
.04 0.01 0.08 0.05
.05 0.03 0.15 0.09
.04 0.02 0.05 0.05
.00 0.03 0.03 0.05ding
Fact
(p
atisfa
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0count. These models used protocol, language, active treatment,
en Fa
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Pill satisfaction and pill bother both discriminated among people
who did and did not adhere to treatment. Patients who adhered to
treatment reported being more satisfied with the pill and less
bothered by the pill than patients who did not adhere to treat-
ment. Because treatment adherence was not available for the in-
jection, it is not surprising that the remaining comparisons were
nonsignificant because they include a measure of injection pref-
erence, satisfaction, or bother. In addition, post-hoc regression
models were considered for each of the individual PSQ to items to
assess if the individual items could distinguish among known
groups as well as the subscales. PSQ items 4a, 4b, and 7a through
7d all discriminated between adherence groups (P  0.01).
All items or subscales, except for injection satisfaction, dis-
criminated among participants with AEs judged by the investiga-
tors as possibly or probably related to the investigational drug
Table 3 – Peformance and Satisfaction Quiestionnaire confi
for the reduced item set.
Item Factor 1
(preference)
Factor 2
(pill satisfaction)
1 0.95 (0.02)
4a 0.82 (0.03)
4b 0.37 (0.06)
4c 0.84 (0.03)
4d 0.67 (0.05)
4e 0.86 (0.03)
4f 0.89 (0.02)
5a
5b
5c
5d
5e
5f
7a
7b
7c
8a
8b
8c
13 0.97 (0.02)
Note: n  721 for this analysis; chi-square 359.79 (df 160), root mean
square residual 0.08. Correlation between Factor 1 and: Factor 2  0.6
(0.05). Correlation between Factor 2 and: Factor 3 0.27 (0.08), Factor 4
Factor 4  0.08 (0.07), and Factor 5  0.53 (0.05). Correlation betwe
Table 4 – Discriminative validity analyses of covariance.
Comparison/subscale Treatmen
F Adherence m
(n  533
Q1. Which do you prefer? 0.73 0.39
Q13. Which would you take long term? 0.33 0.43
Pill satisfaction 12.07† 2.91
Injection satisfaction 0.70 3.43
Pill bother 8.50† 0.39
Injection bother 6.65 0.14
* Measured among patients receiving the active pill only.
† P  0.01.versus those without. Patients who experienced a treatment-re-
latedAE reported a higher preference for the injection and ahigher
propensity toward taking the injection long term. However, the
direction of these effects is difficult to interpret because the treat-
ment-related AEs are not specifically attributed to the pill or injec-
tion. Patients who did not experience an AE related to the study
drug reported being more satisfied with the pill, less bothered by
the pill, and less bothered by the injection than patients who did
experience a treatment-related AE.
Discussion
We have described the development and validation of a question-
naire to evaluate patient preference for a once every 6-months injec-
tion versus aweekly pill for treatment of postmenopausal bone loss.
tory factor analysis and factor loadings (standard errors)
actor 3
njection
isfaction)
Factor 4
(pill bother)
Factor 5
(injection bother)
.84 (0.05)
.40 (0.10)
.84 (0.05)
.82 (0.05)
.92 (0.04)
.58 (0.06)
0.95 (0.01)
0.89 (0.02)
0.95 (0.01)
0.89 (0.03)
0.89 (0.02)
0.94 (0.02)
re error of approximation 0.04, nonnormed fit index 0.99, root mean
5), Factor 3  0.24 (0.08), Factor 4  0.52 (0.05), and Factor 5  0.35
.68 (0.03), and Factor 5 0.01 (0.05). Correlation between Factor 3: and
ctor 4 and Factor 5  0.34 (0.05).
erence* Adverse events (AE) related to
investigational drug
Non-adherence
mean (n  252)
F AE mean
(n  255)
No AE mean
(n  1328)
0.33 9.30† 0.54 0.37
0.46 12.00† 0.62 0.43
2.60 8.72† 2.62 2.85
3.38 0.27 3.42 3.45
0.51 30.58† 0.62 0.41
0.21 15.52† 0.22 0.14rma
F
(i
sat
0
0
0
0
0
0
squa
0 (0.0
0t adh
ean
)
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views, clinical expert input, and direct patient feedback. The results
of the in-depth interviews indicated that the PSQ was easily under-
stood by patients and contained relevant questions.
Results from two large phase 3 trials provided psychometric sup-
port for thePSQanddemonstratedgood internal reliabilityof thePSQ
scales based on Cronbach’s alpha, whereas inter-item correlations
and factor analysis supported the proposed instrument structure,
and ANCOVAs showed that the PSQ is able to distinguish among
knowngroups. The 34-question PSQdemonstrated a factor structure
with five well-defined factors, but with areas of item redundancy.
Twenty items were retained based on cognitive debriefs, and sub-
scales were defined as pill satisfaction, injection satisfaction, pill
bother, and injection bother, with two items eachmeasuring prefer-
ence for the pill or the injection. Although the resulting subscales
showed adequate internal consistency, the Cronbach’s alpha value
for injection bother was smaller than the preferred 0.70, though still
substantial enough to imply a related set of items. All subscales, ex-
cept for injection satisfaction,wereable todistinguishamongknown
groups in a predictable direction.
The two PSQ versions functioned similarly for most items. How-
ever, for the five items that asked about agreement with statements
that referred to the weekly pill (Version A) or the 6-month injection
(Version B) being more convenient, preferable, tolerable, or likely to
continue (items 14a– 14e), the Version B responses more heavily fa-
vored the injection than theVersionA responses (although both ver-
sions showed preference for the injection). Perhaps this could be be-
causepatientsbecomeconfusedwithhaving tobalance thedirection
of the response categories (“strongly agree” to “strongly disagree”)
with the direction of the item stem (e.g., “the weekly pill is more
convenient than the 6-month injection” vs “the 6-month injection is
more convenient than the weekly pill”).
In addition, differences in response frequencies and itemmeans
were found for multiple PSQ items on language. Because great care
was taken in adapting the questionnaire intomultiple languages us-
ing the Task Force for Translation and Cultural Adaptation recom-
mendations [32] followed by cognitive debriefs in the respective
countries, thedifferencesobservedbetweencountries areunlikely to
be caused by wording bias. We speculate that the observed differ-
ences between countries may be explained by small sample sizes
(n 70 for 12 of 18 languages) ormay reflect cultural preferences for
one mode of administration versus another [42–44]. There is no a
priori reason that preference for one modality over another should
differ by the samemagnitude across cultures.
The PSQ seems to be a reasonable measure for accurately as-
sessing if patientswould prefer a once every 6-months injection or
a weekly pill. The PSQmeasures concepts that seem to be relevant
and important to patientswith postmenopausal bone loss needing
treatment. Furthermore, it is a simpleapproach for evaluatingwhich
treatment mode patients prefer, and some of the reasons why they
prefer it (greater satisfaction, less bother). The PSQ is currently being
used in an ongoing open-label clinical trial comparing patient adher-
ence, preference, and satisfactionwith a once every 6-month subcu-
taneous injectionofdenosumabversusweeklyoral alendronate. The
PSQ, however, will have limited applications in other clinical trials,
andpossibly the community settingbecause it is specific for compar-
ing patient preference, satisfaction, and bother between a subcuta-
neous injection administered twice yearly and an oral tablet taken
onceweekly. Also, it is unknown if the PSQwillmap to actual patient
choice in the community setting. At the time the PSQ was adminis-
tered, 6 months had elapsed since patients had experience with the
injection, whereas only one week had passed since they had experi-
ence with the pill. It might be possible that preference for the injec-
tion is a result of patients not remembering any side effects they
experienced with the injection.
Despite the limitations, questionnaires such as the PSQmay be
valuable in assessing patient preference and satisfaction withmedications and these factors may be related to adherence to
treatment and clinician instructions, issues that are especially im-
portant in osteoporosis. Direct patient feedback obtained from
these tools may be used to improve the delivery and quality of
health care. Although this research supports the potential value of
the PSQ, future research should confirm the results using an inde-
pendent sample, evaluate additional properties not considered
here (e.g., convergent/divergent validity), and examine if PSQ
scores map to actual patient choice outside of clinical trials, as
well as treatment adherence and persistence.
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